|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
IMMUNOBIOLOGY
From the Medicine Branch, National Cancer Institute,
National Institutes of Health, Bethesda, MD; Department of Molecular
Medicine, Osaka University Graduate School of Medicine, Suita, Osaka,
Japan.
Receptor usage by viral interleukin-6 (vIL-6), a virokine
encoded by Kaposi sarcoma- associated herpesvirus, is an issue
of controversy. Recently, the crystal structure of vIL-6 identified vIL-6 sites II and III as directly binding to glycoprotein (gp)130, the
common signal transducer for the IL-6 family of cytokines. Site I of
vIL-6, however, comprising the outward helical face of vIL-6, where
human IL-6 (hIL-6) would interact with the specific Kaposi sarcoma (KS)-associated herpesvirus
(KSHV; also called human herpesvirus 8 or HHV-8) is a newly described
oncogenic herpesvirus that is regularly detected in KS lesions from
human immunodeficiency virus (HIV)-infected and noninfected
individuals, primary effusion lymphoma (PEL), and a proportion of
patients with Castleman disease.1 KSHV encodes various
proteins that have features suggesting their roles in promoting
cellular growth and transformation, including viral homologues of
cyclin D, G-protein-coupled receptor, interferon regulatory factor,
macrophage inflammatory proteins, and interleukin-6
(IL-6).2 All these viral proteins display structural
similarities to their cellular counterparts. KSHV viral IL-6 (vIL-6),
encoded at open reading frame (ORF) K2, shares 24.8% amino
acid sequence identity (49.7% similarity) with human IL-6 (hIL-6) and
24.2% identity (47.9% similarity) to murine IL-6
(mIL-6).3-5 As a multifunctional cytokine that acts on a wide variety of cell types, hIL-6 has been implicated in the
pathogenesis of several diseases, including rheumatoid arthritis and
multiple myeloma as well as disorders related to acquired
immunodeficiency syndrome (AIDS).6-8 The IL-6 family of
cytokines exerts its activities via receptor complexes that contain at
least one subunit of the signal transducing protein
gp130.6 The extracellular component of gp130 consists of
an N-terminal immunoglobulin (Ig)-like domain (D1) followed by a
cytokine-binding module (D2D3) and 3 additional fibronectin type
III-like domains (D4D5D6).9,10 This receptor is activated
by the family of IL-6-type cytokines, which includes IL-6, oncostatin
M (OSM), leukemia inhibitory factor (LIF), IL-11, ciliary neurotrophic
factor, and cardiotrophin-1, which exert many overlapping biologic
activities.6 Cell stimulation by any member of the IL-6
family cytokines triggers homodimerization or heterodimerization of
gp130. The dimerization of gp130 leads to activation of associated
Janus kinases and subsequent modification of signal transducers and
activators of transcription (STAT).11,12 In addition to
gp130, the high-affinity, signaling receptor complex for hIL-6 contains
a specific Despite its limited sequence homology, vIL-6 displays many biologic
functions of hIL-6.8 Like cellular IL-6, vIL-6 can stimulate the growth of certain factor-dependent cells, can promote hematopoiesis, can act as an angiogenic factor by inducing vascular endothelial growth factor (VEGF),18 and can activate Janus
kinase 1, STAT1, and STAT3.19 Compared with hIL-6,
however, vIL-6 requires approximately 1000-fold larger amounts of
protein for maximal proliferation of IL-6-dependent cell
lines.20,21 Recently, the crystal structure of vIL-6 has
revealed that vIL-6 shares with other members of the IL-6 family the
canonical up-up-down-down, ABCD 4-helix bundle connected by peptide
loops22 (Figure 1A). In that
study, a soluble tetrameric complex (2:2) of vIL-6 and the 3 NH2-terminal domains (D1D2D3) of gp130 was
crystallized in the absence of IL-6R. Based on this vIL-6-gp130
crystal complex, the unused site I face of vIL-6, where hIL-6 would
interact with IL-6R, is not occupied by gp130 and is sterically
accessible for engagement by other molecules22 (Figure
1B). In cell culture systems, the interaction of vIL-6 with the IL-6R
chains gp130/IL-6R has been uncertain.4,19,20,23-25 The
participation of IL-6R in vIL-6 binding was first deduced from
experiments using the IL-6-dependent murine B9 cells,4
followed by 2 additional reports from the same group that
cotransfection assays involving IL-6R expression vector up-regulated
vIL-6 responses in vitro.23,26 Another group reported that
anti-IL-6R antibody enhanced the inhibitory effect of anti-gp130
antibody in vIL-6-mediated DNA synthesis by INA-6 human
myeloma cells.20 Supportive evidence for a role of IL-6R
in mediating vIL-6 function derived from experiments in which
anti-IL-6R antibody abrogated vIL-6-induced HIV-1 p24 production in a
human monocytic cell line.24 However, other studies showed
that IL-6R was not used by vIL-6 in HepG2 human hepatoma
cells.19 Further, murine pro-B cells expressing
transfected human gp130 but not IL-6R exhibited a strong response to
vIL-6 but not to hIL-6.25 Thus, there seems to be a
consensus that gp130 is used for vIL-6 signaling, but the usage of
IL-6R is uncertain. In this report, we have defined vIL-6 interactions
with the IL-6R/gp130 using surface plasmon resonance and a panel of
newly generated monoclonal antibodies (mAbs) that recognize the
putative vIL-6 site I where hIL-6 would interact with IL-6R.
Preparation of recombinant vIL-6 and its
deletion mutants
Generation of mAbs against vIL-6
Immunoblotting of vIL-6 Immunoblotting of vIL-6 was performed as described previously.27 Briefly, 100 ng MBPvIL-6 cleaved with factor Xa (New England Biolabs), recombinant hIL-6 (a kind gift from Sandoz Pharmaceuticals), and recombinant mIL-6 (Peprotech, Rocky Hill, NJ) were loaded into each well of 10% to 20% tricine-sodium dodecyl sulfate gel (NOVEX, San Diego, CA) after boiling for 10 minutes. The separated proteins were transferred onto polyvinylidene difluoride membranes (Immobilon-P; Millipore, Bedford, MA). Immunostaining was performed using rabbit polyclonal antibodies against MBPvIL-6,18 mIL-6 (Peprotech), or mouse anti-vIL-6 mAbs followed by incubation with horseradish peroxidase (HRP)-conjugated antimouse or rabbit IgG antibodies (Amersham, Piscataway, NJ). Immunocomplexes were visualized using the chemiluminescence detection system (Amersham).Mapping the epitopes recognized by mAbs Full-length and deletion mutants of vIL-6 fusion proteins were immobilized onto 96-well plates (Immulon 4HBX; Dynex Technologies, Chantilly, VA) in phosphate-buffered saline (PBS) by overnight incubation at 4°C. After blocking nonspecific binding with SuperBlock (Pierce), a standard ELISA protocol was followed,28 using appropriate dilutions of anti-vIL-6 antibody and a 1:500 dilution of goat antimouse polyvalent Ig conjugated to alkaline phosphatase (Sigma, St Louis, MO). Reactions were visualized by using P-nitrophenyl phosphate (Sigma), and plates were read at 405 nm with correction at 550 nm using a microplate reader.
ELISA-based binding assay The binding of vIL-6 to IL-6R/gp130 was analyzed by ELISA as described previously with some modifications.29 Purified recombinant human soluble IL-6R (sIL-6R; Endogen, Woburn, MA) and human soluble gp130 (sgp130; R & D Systems, Minneapolis, MN) were immobilized on ELISA plate wells (Immunol 4HBX) at 5 µg/mL in PBS. After blocking the plate with SuperBlock, MBPvIL-6 or hIL-6 was applied at 50 ng/mL in 1% bovine serum albumin (BSA)/PBS, and incubated for 5 hours at room temperature. Bound protein was detected with polyclonal rabbit antibodies directed against vIL-6 or hIL-6 (Peprotech) at 1 µg/mL, followed by an HRP-conjugated antirabbit IgG (Bio-Rad) at 1:3000 in PBS/0.05% Tween 20. Reactions were visualized by using tetramethoxybenzene peroxidase substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD), followed by 2 N H2SO4. The interference of vIL-6 binding to sgp130 by mAbs was analyzed in a similar manner. Biotinylated MBPvIL-621 was incubated at 50 ng/mL in 1% BSA/PBS with anti-vIL-6 mAbs or isotype control murine IgG1 (20 µg/mL) overnight at 4°C. The mixture was applied to the plates coated with sgp130 (2 µg/mL) after SuperBlock treatment. The protein complex was detected by streptavidin-HRP (1:1000; Kirkegaard & Perry Laboratories), and the peroxidase activity was visualized by tetramethoxybenzene peroxidase substrate, followed by 2 N H2SO4. Plates were read at 450 nm with correction at 630 nm using a microplate reader.
Surface plasmon resonance Biospecific interaction analysis was monitored by surface plasmon resonance using BIAcore 2000 system (Biacore, Uppsala, Sweden). The sgp130-Fc (R & D Systems), a fusion protein of sgp130 and human IgG Fc, was immobilized onto the CM5 (carboxymethylated dextran matrix) sensor chip using the amine coupling kit (Biacore), and unreactive groups on the chip were blocked by ethanolamine according to the manufacturer's instructions. A continuous flow (10 µL/mL) of hIL-6 or MBPvIL-6 onto immobilized sgp130-Fc was monitored by passing the analytes across the sensor chip. In parallel experiments, sIL-6R was incubated with hIL-6 and MBPvIL-6 prior to assay. In comparative experiments, a continuous flow (20 µL/mL) of sIL-6R onto immobilized hIL-6 or MBPvIL-6 was monitored in the same manner. The sensor surface was regenerated between assays by 30 seconds of treatment with 10 mM glycine pH 2.2. BIAevaluation 3.0 software (Biacore) was used for all the interaction analyses. The kinetics parameter was calculated according to a 1:1 Langmuir binding model (A + B AB) by direct
fitting of ligand binding sensorgrams at multiple concentrations. The
dissociation equilibrium constant is defined as dissociation constant
(Kd) = dissociation rate constant (kd)/association rate constant
(ka). The Kd was also determined by
Scatchard analysis of equilibrium-state data obtained by a continuous
flow (1 µL/mL) of MBPvIL-6 (50-800 µg/mL) onto immobilized sgp130-Fc, according to previously published
methods.30
vIL-6 bioassays The B9 cell proliferation assay was performed essentially as described.31 B9 cells (2 × 103 cells/well) were incubated in 96-well plates (200 µL/well) with MBPvIL-6 (100 ng/mL) and anti-vIL-6 mAbs (0-10 µg/mL) for 72 hours at 37°C, including a 6-hour terminal pulse with 1 µCi/well of [3H]-thymidine (Amersham, Arlington Heights, IL). Proliferation assays using BAF-130 cells, representing murine BAF-B03 cells expressing transfected human gp130, was performed as described.32 BAF-130 cells were stimulated in 96-well plates (200 µL/well) by MBPvIL-6 or by hIL-6/sIL-6R in the presence or absence of panels of anti-gp130 mAbs (B-R3, B-P8, or B-P4; Cell Sciences, Norwood, MA) for 48 hours at 37°C, including a 6-hour terminal pulse with 1 µCi (0.037 MBq)/well of [3H]-thymidine. [3H]-thymidine incorporation was determined after cell harvesting onto glass fiber filters. The SKW6.4 IgM secretion assay was performed essentially as described.33 SKW6.4 cells (1 × 104 cells/well) were incubated in 96-well plates (200 µL/well) with MBPvIL-6 (0-4 µg/mL) or hIL-6 (0-20 ng/mL) with or without anti-vIL-6 mAbs (0-10 µg/mL) for 96 hours at 37°C. IgM levels in the culture supernatants were measured using a human IgM ELISA quantitation kit (Bethyl Laboratories, Montgomery, TX), according to the manufacturer's instructions. This ELISA does not detect murine IgG (data not shown).
Generation of mAbs against KSHV vIL-6 Based on the recently reported crystal structure of vIL-6, vIL-6 site II binds to D2D3 of gp130 and vIL-6 site III binds to D1 of gp130 (Figure 1). By contrast, site I of vIL-6 is not occupied by gp130 and is sterically accessible by engagement for other molecules.22 To investigate further vIL-6 interactions with its receptor(s), we generated vIL-6-specific mAbs by immunizing mice with the fusion protein of vIL-6 and MBP (MBPvIL-6).18 Following a second screening, 6 anti-vIL-6 mAbs with IgG1 isotype were selected. All 6 mAbs recognized by immunoblotting vIL-6 protein that was obtained by cleaving MBPvIL-6 with factor Xa21 (Figure 2A). These mAbs also detected vIL-6 in cell lysates of the KSHV+ PEL cell line BCP-127 but not in the control KSHV Daudi
cells by Western blotting (data not shown). We examined whether these
mAbs recognize cellular IL-6. Although vIL-6 exhibits 25% amino acid
identity to cellular IL-6, none of these mAbs recognized either hIL-6
or mIL-6. Representative results with one of these mAb are shown in
Figure 1A. A rabbit polyclonal antiserum raised against vIL-6
recognized vIL-6 but not hIL-6 or mIL-6 (Figure 2B), whereas a
polyclonal antiserum against mIL-6 recognized mIL-6 and hIL-6, but not
vIL-6 (Figure 2C). These results suggest that the highly immunogenic
epitopes on vIL-6 are distinct from those of cellular IL-6. The
specific immunogenicity of vIL-6 stands in striking contrast to
Epstein-Barr virus-encoded IL-10 homologue, which is recognized by
many of the monoclonal and polyclonal antibodies against
hIL-10.34
Mapping the epitopes recognized by the mAbs The antigenic epitopes recognized by these vIL-6 mAbs were mapped by ELISA using a panel of vIL-6 deletion mutants. These recombinant proteins were expressed in E coli as MBP fusion molecules and were purified by affinity chromatography (Figure 3). Plate-coating efficiency with fusion proteins was confirmed by reacting with polyclonal anti-MBPvIL-6 antibody (data not shown). All 6 antibodies similarly recognized full-length vIL-6. The mAb v6m13.1.5 bound to a 14-amino acid stretch at the N-terminus of vIL-6, and the mAb v6m24.2.5 recognized 5 amino acids at the C-terminus of vIL-6 (Figure 3). The C-terminal end of hIL-6 is involved in site I binding to IL-6R. The mAbs v6m12.1.1, v6m17.3.2, v6m27.1.2, and v6m31.2.4 bound to full-length MBPvIL-6 and to fragment M3 of MBPvIL-6. This fragment M3, but not other mutants, encompasses an internal 13-amino acid vIL-6 fragment at positions 81 to 93, suggesting that these mAbs map to an epitope that includes Asp81 to Cys93 of vIL-6. The hIL-6 fragment corresponding in aa sequence to this vIL-6 portion occurs in the C-terminal part of the AB-loop and the beginning of helix B, which are also involved in hIL-6 site I. Thus, all mAbs, except for v6m13.1.5 recognize a putative site I on vIL-6.
Neutralizing activity of mAbs in IL-6-responsive cell lines We examined if these mAbs can neutralize vIL-6 bioactivity. vIL-6 has been shown to accelerate the proliferation of murine hybridoma B9 cells but to require approximately 1000-fold larger amounts of protein than hIL-6.18,20,21 The mAbs were cultured at various concentrations with B9 cells in the presence of 100 ng/mL MBPvIL-6. None of these mAbs suppressed the proliferation of B9 cells in response to hIL-6 (data not shown). At the concentrations used, the mAbs v6m13.1.5 and v6m24.2.5 demonstrated no neutralizing activity. By contrast, the mAbs v6m12.1.1, v6m17.3.2, v6m27.1.2, and v6m31.2.4 demonstrated varying degrees of neutralizing activity against vIL-6 (Figure 4A). The mAb v6m31.2.4 exhibited most prominent neutralizing activity in this bioassay. There could be several reasons for the different degrees of neutralizing efficiency, including the possibility that the mAbs recognize somewhat different epitopes within the region of Asp81 to Cys93, that while mapping to the same epitopes, the different mAbs exert variable activity for binding and neutralization,35 or that the differences may be related to the integrity of the antibody molecules. Although the degree of neutralizing activity differed somewhat, all the function-blocking mAbs mapped to the outward helical face of vIL-6 that is not occupied by gp130.
We then confirmed the neutralizing activity of anti-vIL-6 mAbs using the SKW6.4 human B cells that are known to produce IgM in response to hIL-6.33 Like hIL-6, MBPvIL-6 stimulated IgM secretion in SKW6.4 cells in a dose-dependent manner (Figure 4B). Maximal production of IgM was observed with 2 µg/mL MBPvIL-6 and 5 to 10 ng/mL hIL-6. The vIL-6-induced IgM production by SKW6.4 cells was suppressed by mAbs v6m12.1.1, v6m17.3.2, v6m27.1.2, and v6m31.2.4, but only minimally by mAbs v6m13.1.5 and v6m24.2.5 (Figure 4C). The results of these vIL-6 bioassays indicate that clones v6m12.1.1, v6m17.3.2, v6m27.1.2, and v6m31.2.4 have specific neutralizing activity against vIL-6. Lack of neutralizing activity by the mAb v6m24.2.5, which recognizes the C-terminal end of vIL-6 (Figure 3), represents a clear difference from mAb against the C-terminal end of hIL-6 binding, which completely blocked hIL-6 activity by presumably disrupting IL-6R binding.14 Binding of vIL-6 to sgp130 in the absence of sIL-6R Because our neutralizing mAbs recognize the putative site I face of vIL-6, which corresponds to the putative IL-6R binding site in hIL-6, we examined vIL-6 binding to IL-6R. Using recombinant purified human sIL-6R and sgp130, soluble forms of IL-6R and gp130 lacking the transmembrane and cytoplasmic regions, we tested if vIL-6 could bind to these proteins individually or after they have been incubated together in a cell-free system. Purified sIL-6R or sgp130 or both were immobilized onto a 96-well dish, and vIL-6 binding was detected by polyclonal antibody against vIL-6. In parallel, hIL-6 was used as a control and detected by polyclonal antibody against hIL-6. As expected, hIL-6 bound to sIL-6R but not to sgp130 alone (Figure 5). When sIL-6R and sgp130 were first incubated together and then immobilized onto wells, the binding of hIL-6 was reduced, likely reflecting the failure of polyclonal anti-hIL-6 antibody to bind hIL-6 sites II and III that were occupied by sgp130. Noteworthy, MBPvIL-6 bound to wells coated with sgp130 but not to wells coated with sIL-6R alone (Figure 5). The binding of vIL-6 to sgp130 was minimally affected by preincubation of sgp130 with sIL-6R, suggesting that sIL-6R did not interfere with anti-vIL-6 polyclonal antibody attachment to vIL-6 site I. In parallel experiments, sIL-6R and sgp130 immobilized on a plate failed to bind to MBP (data not shown). Lack of IL-6R contribution to vIL-6/gp130 binding was further confirmed by surface plasmon resonance. The CM5 sensor chip immobilized with sgp130 was used for equilibrium binding analysis on the BIAcore system. As shown in Figure 6A, hIL-6 showed strong binding to sgp130 only when preincubated with sIL-6R. In contrast, vIL-6 bound to sgp130 without sIL-6R, and vIL-6 preincubation with sIL-6R minimally increased binding affinity for sgp130 (Figure 6B). In accordance with these observations, sIL-6R bound to the CM5 sensor chip immobilized with hIL-6 but not MBPvIL-6 even though MBPvIL-6 was used at up to 2.2-times higher amount than that of hIL-6 (data not shown). A range of MBPvIL-6 concentrations was injected over the immobilized surface of sgp130, and, as a control, MBP (Figure 6C). Control MBP showed minimal signal increase over baseline. Binding of MBPvIL-6 to sgp130 demonstrated concentration dependence and saturability. Using a 1:1 Langmuir binding model, sensograms yielded a ka of 980 1/M · s, kd of 2.2 × 103 1/s and Kd of 2.2 µM.
Additional BIAcore data (not shown) of MBPvIL-6 binding to immobilized
sgp130 at equilibrium was analyzed by Scatchard analysis. Using this
method, the Kd for the vIL-6-gp130 interaction was
calculated at 2.5 µM, which is comparable to the Kd
obtained by the 1:1 Langmuir binding model. Previously, the affinity of
hIL-6/sIL-6R complex for gp130 yielded a Kd of 1.7 nM.36 Thus, the binding affinity of vIL-6 for sgp130 is
1000-fold lower than that of hIL-6/sIL-6R complex to gp130. Together,
these experiments demonstrate that vIL-6 can bind to gp130 but not
IL-6R.
The gp130 binding surfaces are not fully shared by hIL-6, and vIL-6 The results from the binding assays strongly suggested that the neutralizing activity by anti-vIL-6 mAbs is not attributable to blocking vIL-6 binding to IL-6R. We therefore examined if the binding of vIL-6 to gp130 in a cell-free system could be inhibited by neutralizing mAbs to vIL-6. Biotinylated vIL-6 (50 ng/mL) was first incubated with control mouse IgG1 (20 µg/mL) or anti-vIL-6 mAbs (20 µg/mL) overnight at 4°C, and then tested for binding to sgp130 bound to ELISA plates. Compared with the isotype control murine IgG1, the 4 anti-vIL-6 neutralizing mAbs interfered with the binding of vIL-6 to sgp130, whereas the 2 nonneutralizing mAbs did not (Figure 7). These results provide evidence that the mAbs against vIL-6 exert neutralizing activity by direct inhibition of vIL-6 binding to gp130.
We then examined if the vIL-6 epitope that our neutralizing mAbs
recognize is used as a direct binding surface for gp130. A recent
report has shown that vIL-6 induces the expression of hIL-6 in certain
cell lines.37 mIL-6 is species specific, whereas hIL-6
binds to both human and murine receptors. To exclude a potential contribution of vIL-6-induced cellular IL-6, we used murine BAF-B03 cells stably transfected with human gp130. This cell line is known to
respond to vIL-6 but not to hIL-6 in the absence of
sIL-6R.19,32 As expected, hIL-6/sIL-6R induced DNA
synthesis in BAF-130 cells (Figure 8A).
In agreement with its lower binding affinity, vIL-6 had much lower
specific activity than hIL-6/sIL-6R. The vIL-6 deletion mutant MBPvIL-6
M3, which contains the region of Asp81 to Cys93 within site I
but lacks full sites II and III comprising the reported vIL-6 interface
with gp130 (Figures 1 and 3), did not induce DNA synthesis in BAF-130
cells or compete for vIL-6 or hIL-6/sIL-6R binding to gp130 (Figure
8B). This suggested either that this vIL-6 epitope is not part of the
vIL-6 binding surface to gp130, as shown by the vIL-6 crystal
structure, or that this fragment alone is not sufficient for biologic
activity. Neither parental BAF-B03 cells nor mock transfectants
responded to vIL-6 (data not shown).
We then examined if hIL-6 and vIL-6 share the same gp130 binding sites using a panel of anti-gp130 mAbs. These antibodies are known to recognize specific functional sites of gp130 for signal transduction by IL-6-type cytokines.38,39 As reported previously, all 3 anti-gp130 mAbs, B-R3, B-P4 and B-P8, but not an isotype control, inhibited hIL-6-induced DNA synthesis in BAF-130 cells (Figure 8C). By contrast, when stimulated with vIL-6, mAbs B-R3 and B-P4, but not B-P8, suppressed DNA synthesis in BAF-130 cells.39,40 The mAb B-P4 recognizes the membrane-proximal extracellular part of gp130 (D4D5D6) that is critical for homodimerization of gp130.40 The B-R3 mAb interferes with gp130 binding by all IL-6 family cytokines, whereas B-P8 mAb interferes with gp130 binding by hIL-6 and ciliary neurotrophic factor.38,40 The mAbs B-R3 and B-P8 recognize the epitopes in gp130 D2 and D3, respectively, which constitute the cytokine-binding module.38,39 These results provide evidence that hIL-6 and vIL-6 share an epitope in D2 of gp130 and that both cytokines induce homodimerization of gp130. The results further suggest that vIL-6 does not bind to the epitope in gp130 D3, which is critical to hIL-6 function.
The KSHV vIL-6 is one of the viral proteins implicated in the pathogenesis of AIDS-related malignancies.18,27,41,42 vIL-6 can stimulate the growth of PEL cells in an autocrine/paracrine fashion21 and induce VEGF expression, which is critical for the growth of PEL and KS in vivo.18,43-46 A proportion of HIV+ patients have detectable vIL-6 in sera and body fluids,27,41,42 suggesting that this virokine may play a critical role in the pathogenesis of AIDS-associated malignancies by promoting sustained phosphorylation of gp130. Although vIL-6 shows biologic functions similar to those of cellular IL-6, the interaction between vIL-6 and its receptor(s) is unclear. Cellular IL-6 exerts its actions through a receptor complex consisting of a specific IL-6-binding protein, IL-6R, and a signal-transducing subunit, gp130. The IL-6/IL-6R complex induces the homodimerization of 2 gp130 molecules leading to a number of intracellular signaling events, including activation of the transcription factor NF-IL-6 and STAT3 via phosphorylation of the Janus kinase.6,11,12 Cellular IL-6 is unable to transduce signals in the absence of IL-6R. The potential participation of IL-6R in vIL-6 binding was first supported by the experiments using the IL-6-dependent B9 cells.4,20 Moreover, cotransfection assay involving IL-6R expression vector enhanced vIL-6 responses.23,26 However, anti-IL-6R antibody effectively neutralized STAT phosphorylation in HepG2 cells in response to hIL-6 but failed to block STAT activation by vIL-6.19 In contrast, anti-gp130 antibody abrogated signaling of both responses.19 Furthermore, BAF-B03 cells expressing transfected human gp130 but not IL-6R, exhibited a strong response to vIL-6 but not to hIL-6.25 Recently, crystallographic analysis of the vIL-6/sgp130 complex showed that site I of vIL-6 is not occupied by gp130 and is fully accessible within the complex,22 raising again the possibility that this site might engage IL-6R. Here, we provide evidence that vIL-6 does not bind to IL-6R in a cell-free system. By both surface plasmon resonance and ELISA, vIL-6 bound gp130 without a need for IL-6R and failed to bind IL-6R. In addition, mAb v6m24.2.5 recognizing the C-terminal end of helix D of vIL-6 did not show neutralizing activity in bioassays. In contrast to these results with vIL-6, the corresponding C-terminal end of helix D in hIL-6 is included in the binding face to IL-6R, and the binding of mAb to this region totally abrogated hIL-6 activity by blocking the ligand interaction to IL-6R.14 Recently, Mori and coworkers documented that vIL-6 can induce the expression of cellular IL-6 in certain cell types.37 Another report has noted that VEGF stimulates stromal cells to produce hIL-6.47 Because vIL-6 is a potent inducer of VEGF,18 vIL-6 could also stimulate hIL-6 expression through induction of VEGF. Expression of the IL-6 gene is regulated by cis-acting elements that differ depending on the cell type and nature of the activating agent.6 The presence of hIL-6 could be a confounding factor in cell-based systems used to study vIL-6 receptor usage and may explain some of the contrasting results in the literature. Using the structure of the growth hormone/growth hormone receptor complex as a paradigm for cytokine receptor complex assembly, IL-6-type cytokines are believed to have 3 topologically discrete sites of interactions with their receptors. Site I, if used, is always engaged by a nonsignaling receptor: IL-6R, IL-11R, or ciliary neurotrophic factor receptor. Site II is always engaged by gp130, and site III by a second signaling receptor gp130, OSMR, or LIFR.48 Within gp130, 3 binding epitopes have been identified as critical to its activation by hIL-6/IL-6R: one epitope involves the Ig-like domain (D1); another epitope is located in the cytokine binding module (D2D3); and the other is located in the membrane-proximal extracellular domains (D4D5D6).40 According to the crystallographic analysis of the vIL-6/sgp130 (D1D2D3) complex,22 sequence alignment of hIL-6 and vIL-6 shows that contact residues seen in the structure of the vIL-6/gp130 complex are in the same positions as hIL-6-gp130 contact residues previously mapped by mutagenesis.49 In cell culture, the membrane-proximal extracellular part of gp130 (D4D5D6) is critical for vIL-6-mediated signaling, even though vIL-6 can form a tetrameric complex with gp130 (D1D2D3).22 Further, although hIL-6 and vIL-6 share an epitope in gp130 D2, vIL-6 does not appear to use an epitope in gp130 D3 that is critical to hIL-6 function. Together with the evidence that vIL-6 does not bind IL-6R, these results are consistent with the previous observation that vIL-6 did not compete with the hIL-6 superantagonist Sant7 for human myeloma cell stimulation.20 Continued analysis using gp130 mutants and h/vIL-6 chimeras will be important to identify the specificity-determining epitopes that are essential for binding and signaling by hIL-6 and vIL-6. It is generally believed that receptor conformational changes occur in
a sequential process following ligand-receptor
engagement.50 In addition, some ligands need allosteric
changes to achieve high-affinity binding to their
receptors.51-53 On receptor binding, the flexible AB-loop
of interferon-
We thank Mike Klutch for help with DNA sequence analysis and Dr Fumihiko Takeshita for providing SKW6.4 cells. We also thank Drs Peter Steinbach, Fred Dyda, Demetrios Braddock, and Motomu Shimaoka for critical discussions, and Dr Issey Okazaki for his technical help with the BIAcore analysis.
Submitted April 26, 2001; accepted July 17, 2001.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Presented in part at the 42nd annual meeting of the American Society of Hematology, December 4, 2000, in San Francisco, CA. Reprints: Yoshiyasu Aoki, Medicine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr, Rm 12N226 MSC1907, Bethesda, MD 20892; e-mail: aokiy{at}mail.nih.gov.
1.
Cesarman E, Mesri EA, Gershengorn MC.
Viral G protein-coupled receptor and Kaposi's sarcoma: a model of paracrine neoplasia?
J Exp Med.
2000;191:417-422 2. Boshoff C, Weiss RA. Kaposi's sarcoma-associated herpesvirus. Adv Cancer Res. 1998;75:57-86[Medline] [Order article via Infotrieve].
3.
Moore PS, Boshoff C, Weiss RA, Chang Y.
Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV.
Science.
1996;274:1739-1744 4. Nicholas J, Ruvolo VR, Burns WH, et al. Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat Med. 1997;3:287-292[CrossRef][Medline] [Order article via Infotrieve]. 5. Neipel F, Albrecht JC, Ensser A, et al. Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol. 1997;71:839-842[Abstract].
6.
Kishimoto T, Akira S, Narazaki M, Taga T.
Interleukin-6 family of cytokines and gp130.
Blood.
1995;86:1243-1254
7.
Hallek M, Bergsagel PL, Anderson KC.
Multiple myeloma: increasing evidence for a multistep transformation process.
Blood.
1998;91:3-21 8. Aoki Y, Jones KD, Tosato G. Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. J Hematother Stem Cell Res. 2000;9:137-145[CrossRef][Medline] [Order article via Infotrieve]. 9. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 1990;63:1149-1157[CrossRef][Medline] [Order article via Infotrieve]. 10. Bravo J, Staunton D, Heath JK, Jones EY. Crystal structure of a cytokine-binding region of gp130. EMBO J. 1998;17:1665-1674[CrossRef][Medline] [Order article via Infotrieve].
11.
Narazaki M, Witthuhn BA, Yoshida K, et al.
Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130.
Proc Natl Acad Sci U S A.
1994;91:2285-2289 12. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol. 1997;15:797-819[CrossRef][Medline] [Order article via Infotrieve]. 13. Somers W, Stahl M, Seehra JS. 1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling. EMBO J. 1997;16:989-997[CrossRef][Medline] [Order article via Infotrieve]. 14. Brakenhoff JP, Hart M, De Groot ER, Di Padova F, Aarden LA. Structure-function analysis of human IL-6. Epitope mapping of neutralizing monoclonal antibodies with amino- and carboxyl-terminal deletion mutants. J Immunol. 1990;145:561-568[Abstract]. 15. Savino R, Ciapponi L, Lahm A, et al. Rational design of a receptor super-antagonist of human interleukin-6. EMBO J. 1994;13:5863-5870[Medline] [Order article via Infotrieve]. 16. Savino R, Lahm A, Salvati AL, et al. Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp130 activation. EMBO J. 1994;13:1357-1367[Medline] [Order article via Infotrieve].
17.
Kalai M, Montero-Julian FA, Grotzinger J, et al.
Analysis of the human interleukin-6/human interleukin-6 receptor binding interface at the amino acid level: proposed mechanism of interaction.
Blood.
1997;89:1319-1333
18.
Aoki Y, Jaffe ES, Chang Y, et al.
Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6.
Blood.
1999;93:4034-4043
19.
Molden J, Chang Y, You Y, Moore PS, Goldsmith MA.
A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL- 6) activates signaling through the shared gp130 receptor subunit.
J Biol Chem.
1997;272:19625-19631
20.
Burger R, Neipel F, Fleckenstein B, et al.
Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells.
Blood.
1998;91:1858-1863
21.
Jones KD, Aoki Y, Chang Y, Moore PS, Yarchoan R, Tosato G.
Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells.
Blood.
1999;94:2871-2879
22.
Chow D, He X, Snow AL, Rose-John S, Garcia KC.
Structure of an extracellular gp130 cytokine receptor signaling complex.
Science.
2001;291:2150-2155
23.
Wan X, Wang H, Nicholas J.
Human herpesvirus 8 interleukin-6 (vIL-6) signals through gp130 but has structural and receptor-binding properties distinct from those of human IL-6.
J Virol.
1999;73:8268-8278 24. Gage JR, Breen EC, Echeverri A, et al. Human herpesvirus 8-encoded interleukin 6 activates HIV-1 in the U1 monocytic cell line. AIDS. 1999;13:1851-1855[CrossRef][Medline] [Order article via Infotrieve].
25.
Mullberg J, Geib T, Jostock T, et al.
IL-6 receptor independent stimulation of human gp130 by viral IL-6.
J Immunol.
2000;164:4672-4677
26.
Li H, Wang H, Nicholas J.
Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino acid residues of vIL-6 important for IL-6R-dependent and -independent signaling.
J Virol.
2001;75:3325-3334
27.
Aoki Y, Yarchoan R, Braun J, Iwamoto A, Tosato G.
Viral and cellular cytokines in AIDS-related malignant lymphomatous effusions.
Blood.
2000;96:1599-1601
28.
Kellam P, Bourboulia D, Dupin N, et al.
Characterization of monoclonal antibodies raised against the latent nuclear antigen of human herpesvirus 8.
J Virol.
1999;73:5149-5155
29.
Ozbek S, Grotzinger J, Krebs B, et al.
The membrane proximal cytokine receptor domain of the human interleukin-6 receptor is sufficient for ligand binding but not for gp130 association.
J Biol Chem.
1998;273:21374-21379 30. Ward LD, Howlett GJ, Hammacher A, et al. Use of a biosensor with surface plasmon resonance detection for the determination of binding constants: measurement of interleukin-6 binding to the soluble interleukin-6 receptor. Biochemistry. 1995;34:2901-2907[CrossRef][Medline] [Order article via Infotrieve].
31.
Jones K, Rivera C, Sgadari C, et al.
Infection of human endothelial cells with Epstein-Barr virus.
J Exp Med.
1995;182:1213-1221
32.
Narazaki M, Yasukawa K, Saito T, et al.
Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130.
Blood.
1993;82:1120-1126
33.
Peppard JV, Loo P, Sills MA, Munster D, Pomponi SA, Wright AE.
Characterization of an interleukin 6 cytokine family antagonist protein from a marine sponge, Callyspongia sp.
J Biol Chem.
1996;271:7281-7284 34. Taga H, Taga K, Wang F, Chretien J, Tosato G. Human and viral interleukin-10 in acute Epstein-Barr virus-induced infectious mononucleosis. J Infect Dis. 1995;171:1347-1350[Medline] [Order article via Infotrieve].
35.
Huang C, Zang Q, Takagi J, Springer TA.
Structural and functional studies with antibodies to the integrin beta 2 subunit. A model for the I-like domain.
J Biol Chem.
2000;275:21514-21524
36.
Horsten U, Muller-Newen G, Gerhartz C, et al.
Molecular modeling-guided mutagenesis of the extracellular part of gp130 leads to the identification of contact sites in the interleukin-6 (IL-6).IL-6 receptor.gp130 complex.
J Biol Chem.
1997;272:23748-23757 37. Mori Y, Nishimoto N, Ohno M, et al. Human herpesvirus 8-encoded interleukin-6 homologue (viral IL-6) induces endogenous human IL-6 secretion. J Med Virol. 2000;61:332-335[CrossRef][Medline] [Order article via Infotrieve]. 38. Wijdenes J, Heinrich PC, Muller-Newen G, et al. Interleukin-6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies. Eur J Immunol. 1995;25:3474-3481[Medline] [Order article via Infotrieve].
39.
Muller-Newen G, Kuster A, Wijdenes J, Schaper F, Heinrich PC.
Studies on the interleukin-6-type cytokine signal transducer gp130 reveal a novel mechanism of receptor activation by monoclonal antibodies.
J Biol Chem.
2000;275:4579-4586
40.
Kurth I, Horsten U, Pflanz S, et al.
Importance of the membrane-proximal extracellular domains for activation of the signal transducer glycoprotein 130.
J Immunol.
2000;164:273-282
41.
Aoki Y, Yarchoan R, Wyvill K, Okamoto S, Little RF, Tosato G.
Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders.
Blood.
2001;97:2173-2176
42.
Aoki Y, Tosato G, Fonville TW, Pittaluga S.
Serum viral interleukin-6 in AIDS-related multicentric Castleman disease.
Blood.
2001;97:2526-2527
43.
Aoki Y, Tosato G.
Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphomas.
Blood.
1999;94:4247-4254
44.
Aoki Y, Tosato G, Nambu Y, Iwamoto A, Yarchoan R.
Detection of vascular endothelial growth factor in AIDS-related primary effusion lymphomas.
Blood.
2000;95:1109-1110
45.
Munshi N, Groopman JE, Gill PS, Ganju RK.
c-Src mediates mitogenic signals and associates with cytoskeletal proteins upon vascular endothelial growth factor stimulation in Kaposi's sarcoma cells.
J Immunol.
2000;164:1169-1174
46.
Tulpule A, Scadden DT, Espina BM, et al.
Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma.
J Clin Oncol.
2000;18:716-723
47.
Dankbar B, Padro T, Leo R, et al.
Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.
Blood.
2000;95:2630-2636 48. Bravo J, Heath JK. Receptor recognition by gp130 cytokines. EMBO J. 2000;19:2399-2411[CrossRef][Medline] [Order article via Infotrieve]. 49. Simpson RJ, Hammacher A, Smith DK, Matthews JM, Ward LD. Interleukin-6: structure-function relationships. Protein Sci. 1997;6:929-955[Medline] [Order article via Infotrieve]. 50. Heldin CH. Dimerization of cell surface receptors in signal transduction. Cell. 1995;80:213-223[CrossRef][Medline] [Order article via Infotrieve]. 51. Walter MR, Windsor WT, Nagabhushan TL, et al. Crystal structure of a complex between interferon-gamma and its soluble high-affinity receptor. Nature. 1995;376:230-235[CrossRef][Medline] [Order article via Infotrieve]. 52. Hage T, Sebald W, Reinemer P. Crystal structure of the interleukin-4/receptor alpha chain complex reveals a mosaic binding interface. Cell. 1999;97:271-281[CrossRef][Medline] [Order article via Infotrieve]. 53. Lee JO, Bankston LA, Arnaout MA, Liddington RC. Two conformations of the integrin A-domain (I-domain): a pathway for activation? Structure. 1995;3:1333-1340[Medline] [Order article via Infotrieve]. 54. Li T, Horan T, Osslund T, Stearns G, Arakawa T. Conformational changes in G-CSF/receptor complex as investigated by isotope-edited FTIR spectroscopy. Biochemistry. 1997;36:8849-8857[CrossRef][Medline] [Order article via Infotrieve].
55.
Lu C, Shimaoka M, Zang Q, Takagi J, Springer TA.
Locking in alternate conformations of the integrin alpha Lbeta 2 I domain with disulfide bonds reveals functional relationships among integrin domains.
Proc Natl Acad Sci U S A.
2001;98:2393-2398
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  P. Gasperini, S. Sakakibara, and G. Tosato Contribution of viral and cellular cytokines to Kaposi's sarcoma-associated herpesvirus pathogenesis J. Leukoc. Biol., October 1, 2008; 84(4): 994 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Chen and J. Nicholas Structural Requirements for gp80 Independence of Human Herpesvirus 8 Interleukin-6 (vIL-6) and Evidence for gp80 Stabilization of gp130 Signaling Complexes Induced by vIL-6 J. Virol., October 1, 2006; 80(19): 9811 - 9821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kovaleva, I. Bussmeyer, B. Rabe, J. Grotzinger, E. Sudarman, J. Eichler, U. Conrad, S. Rose-John, and J. Scheller Abrogation of Viral Interleukin-6 (vIL-6)-Induced Signaling by Intracellular Retention and Neutralization of vIL-6 with an Anti-vIL-6 Single-Chain Antibody Selected by Phage Display. J. Virol., September 1, 2006; 80(17): 8510 - 8520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Fielding, R. M. McLoughlin, C. S. Colmont, M. Kovaleva, D. A. Harris, S. Rose-John, N. Topley, and S. A. Jones Viral IL-6 Blocks Neutrophil Infiltration during Acute Inflammation J. Immunol., September 15, 2005; 175(6): 4024 - 4029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Meads and P. G. Medveczky Kaposi's Sarcoma-associated Herpesvirus-encoded Viral Interleukin-6 Is Secreted and Modified Differently Than Human Interleukin-6: EVIDENCE FOR A UNIQUE AUTOCRINE SIGNALING MECHANISM J. Biol. Chem., December 10, 2004; 279(50): 51793 - 51803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Dela Cruz, Y. Lee, S. R. Viswanathan, A. S. El-Guindy, J. Gerlach, S. Nikiforow, D. Shedd, L. Gradoville, and G. Miller N-linked Glycosylation Is Required for Optimal Function of Kaposi's Sarcoma Herpesvirus-encoded, but Not Cellular, Interleukin 6 J. Exp. Med., February 17, 2004; 199(4): 503 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Underhill-Day, L. A. McGovern, N. Karpovich, H. J. Mardon, V. A. Barton, and J. K. Heath Functional Characterization of W147A: A High-Affinity Interleukin-11 Antagonist Endocrinology, August 1, 2003; 144(8): 3406 - 3414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Aoki, G. M. Feldman, and G. Tosato Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma Blood, February 15, 2003; 101(4): 1535 - 1542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Deng, J. T. Chu, M. B. Rettig, O. Martinez-Maza, and R. Sun Rta of the human herpesvirus 8/Kaposi sarcoma-associated herpesvirus up-regulates human interleukin-6 gene expression Blood, August 13, 2002; 100(5): 1919 - 1921. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
-chain IL-6
receptor (IL-6R), is accessible and not occupied by gp130. This study
examined whether this unused vIL-6 surface is available for IL-6R
binding. By enzyme-linked immunosorbent assay, vIL-6 bound to soluble
gp130 (sgp130) but not to soluble IL-6R (sIL-6R). Using plasmon surface
resonance, vIL-6 bound to sgp130 with a dissociation constant of 2.5 µM, corresponding to 1000-fold lower affinity than that of
hIL-6/sIL-6R complex for gp130. sIL-6R neither bound to vIL-6 nor
affected vIL-6 binding to gp130. In bioassays, vIL-6 activity was
neutralized by 4 monoclonal antibodies (mAbs) recognizing a domain
within vIL-6 site I, mapped to the C-terminal part of the AB-loop and
the beginning of helix B. The homologous region in hIL-6 participates
in site I binding to IL-6R. In addition, binding of vIL-6 to sgp130 was
interfered with specifically by the 4 neutralizing anti-vIL-6 mAbs.
Based on the vIL-6 crystal structure, the vIL-6 neutralizing mAbs map outside the binding interface to gp130, suggesting that they either produce allosteric changes or block necessary conformational changes in
vIL-6 preceding its binding to gp130. These results document that vIL-6
does not bind IL-6R and suggest that conformational change may be
critical to vIL-6 function.
(Blood. 2001;98:3042-3049)
) when the absorbance was similar (within 0.05 absorbance
units) to the background. The black box represents the putative vIL-6
signal peptide portion.
undergoes a conformational change to facilitate receptor binding.